Literature DB >> 1353143

Prenatal screening for cystic fibrosis.

M E Mennie1, A Gilfillan, M Compton, L Curtis, W A Liston, I Pullen, D A Whyte, D J Brock.   

Abstract

Screening for carriers of CF (cystic fibrosis) is now possible but the best way of delivering such a service is unknown. In one model 4348 women attending antenatal clinics in an Edinburgh maternity hospital were invited to participate in a trial of prenatal screening. Mouthwash samples were tested for six CF alleles (85% of mutant genes) and when a woman was found to be a CF carrier her partner was also tested. Heterozygous couples were offered prenatal diagnosis. 609 (14%) women declined to enter the trial and another 574 (13%) were not screened, usually because of late booking. Among the remaining 3165 women there were 111 carriers of a CF gene (1 in 29). 4 of these 111 had carrier partners and these couples opted for prenatal diagnosis, the 1 pregnancy with an affected fetus being terminated. The psychological impact of screening was assessed by the general health questionnaire. There was a significant increase in stress at the time of the test result among women identified as carriers. However, this disappeared when their male partners tested normal and did not reappear later in the pregnancy. By providing time for couples to discuss the possibility of screening and by offering the test at a point (the antenatal booking clinic) at which most pregnant women are seen, this approach has advantages, provided that counselling is readily available.

Entities:  

Keywords:  Edinburgh; Genetics and Reproduction

Mesh:

Year:  1992        PMID: 1353143     DOI: 10.1016/0140-6736(92)90476-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

Review 1.  Economic notes. Discounting.

Authors:  D J Torgerson; J Raftery
Journal:  BMJ       Date:  1999-10-02

Review 2.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

3.  Attitudes toward cystic fibrosis carrier and prenatal testing and utilization of carrier testing among relatives of individuals with cystic fibrosis.

Authors:  DeeDee Lafayette; Dianne Abuelo; Mary Ann Passero; Umadevi Tantravahi
Journal:  J Genet Couns       Date:  1999-02       Impact factor: 2.537

4.  Implications of carrier identification in newborn screening for cystic fibrosis.

Authors:  E P Parsons; A J Clarke; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

5.  Cystic fibrosis genotypes and views on screening are both heterogeneous and population related.

Authors:  C R Scriver; T M Fujiwara
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

6.  Cystic fibrosis carrier population screening in the primary care setting.

Authors:  S Loader; P Caldwell; A Kozyra; J C Levenkron; C D Boehm; H H Kazazian; P T Rowley
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

7.  Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations.

Authors:  Pascal Borry; Gerry Evers-Kiebooms; Martina C Cornel; Angus Clarke; Kris Dierickx
Journal:  Eur J Hum Genet       Date:  2009-03-11       Impact factor: 4.246

8.  Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population.

Authors:  U Jung; U Urner; K Grade; C Coutelle
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

9.  Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening.

Authors:  E W Clayton; V L Hannig; J P Pfotenhauer; R A Parker; P W Campbell; J A Phillips
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

10.  Cystic fibrosis heterozygote screening in 5,161 pregnant women.

Authors:  D R Witt; C Schaefer; P Hallam; S Wi; B Blumberg; A Fishbach; J Holtzman; S Kornfeld; R Lee; L Nemzer; R Palmer
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.